Feature

Alto disrupting the trial-and-error approach to treating neuropsychiatric disorders

Alto Neuroscience (NYSE: ANRO) is aiming to redefine the way neuropsychiatric conditions are treated through a biology-driven pipeline designed to deliver more effective treatment options. Drawing on expertise in...

August 4, 2026

Feature

In conversation with Jen Sharpe, partner, advisory services, at IntegriChain, and founder of the Revenue Analytics Collaboration

A pharmaceutical and life sciences technology, data, and consulting platform, IntegriChain delivers solutions that help companies manage the commercial and financial complexities of bringing therapies to market...

July 21, 2026

Feature

Adaptin Bio is leveraging immune cell hitchhiking to target brain tumors

Adaptin Bio (OTCQB: APTN) is advancing a novel strategy to overcome one of the most persistent challenges in neuro-oncology—delivering effective therapies across the blood-brain barrier. By leveraging the natural...

July 14, 2026

Feature

Senti Biosciences outsmarting complex disease with next-gen cell and gene therapies

Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable...

July 7, 2026